News QData MS Research Platform Aims for Better Patient Treatment, Care QData MS Research Platform Aims for Better Patient Treatment, Care Understanding MS journey by combining electronic records and doctor notes by Mary Chapman | November 21, 2022 Share this article: Share article via email Copy article link With a goal of betterĀ treatment and care for people withĀ multiple sclerosis (MS), Verana Health is developing a neurology module for disease research that includes de-identified and curated real-world data covering more than 30,000 MS patients. The digital health company is developing Qdata MS to give healthcare providers, researchers, and life science companies a better understanding of the patient journey based on electronic health record (EHR) data and clinician notes. Such notes are related to the diagnosis, treatment, and trajectory of the disease, thought to affect nearly one million U.S. residents. Qdata MS will join other VeranaĀ disease-specific, fit-for-purpose data modules designed to inform research outcomes and drive insights into therapeutic and medical device development, the company stated in a press release. Recommended Reading November 18, 2022 Columns by Ed Tobias The MS Hug: A Frightening Embrace You’d Rather Not Have Helping ‘researchers develop and study treatments for various MS patients’ The Qdata platform is powered by VeraQ, a population health data engine enhanced by artificial intelligence (AI) that ingests, links, and curates data from more than 20,000 healthcare providers spanning neurology, ophthalmology, and urology.Ā Collectively, the modules include records from more than 90 million de-identified patients and 70 EHR systems, and results in research-ready data that can be used with clinical studies, the company reported. In MS, curated, de-identified real-world data from patients can help offer insights into how patients are living with the disease and reacting to treatments. Qdata MS uses the American Academy of Neurologyās Axon patient registry that collects, reports, and analyzes real-world EHR data, and is managed by VeraQ. āQdata MS gives patients and their physicians the opportunity to contribute and lend their anonymized experiences to research,ā said Heather Moss, MD, PhD, Verana Health’s medical advisor. āQdata MS has the potential to provide a more granular view of the MS patient journey that is not easily found within structured EHR fields, medical claims, or pharmacy claims,” added Moss, who is also an associate professor atĀ Stanford University. “The ability to bring meaning to unstructured, de-identified neurologist notes on tens of thousands of MS patients will provide a valuable new dataset to help researchers develop and study treatments for various MS patient cohorts.ā Specifically, Qdata MS provides access to key disease measures, such as disability progression and relapse rate, that are derived from EHR clinician notes. Such variables and clinical outcomesĀ can be analyzed across large populations to understand the clinical journey of MS patients. The module is expected to support more optimized study designs, helping investigators understand and track the patient journey, and providing information regarding patients’ response to treatment. āQdata MS will help support MS researchers in accessing insightful [real-world evidence] and allow practices enrolled in the Axon registry to potentially participate in or help influence groundbreaking clinical research,ā said Sujay Jadhav, Verana Health’s CEO. āBy making this de-identified data available, the American Academy of Neurology and Verana Health are enabling MS researchers to gain a better understanding of this disease and how it can be treated.ā In addition to MS, Verana is developing neurology modules inĀ Parkinsonās disease, neuromyelitis optica spectrum disorder, and other neurological conditions. Qdata SMA, Verana Healthās first neurology module, was introduced forĀ spinal muscular atrophy in April. Print This Page About the Author Mary Chapman Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. Sheās won a Society of Professional Journalists award for outstanding reporting. Tags artificial intelligence, MS research
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8